Icon

BENICAR HCT (nda021532)- (12.5MG;20MG,12.5MG;40MG,25MG;40MG)

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL COSETTE
12.5MG;20MG,12.5MG;40MG,25MG;40MG
Yes No
2022-May-19 Expired
None None
None No
BENICAR HCT is a combination of olmesartan, an angiotensin II receptor blocker and hydrochlorothiazide, a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure.
10 0 7
Total Other Developers 4
Drugs with Suitability No
12.5MG;20MG ** ** Up - 6
12.5MG;40MG ** ** - - 6
25MG;40MG ** ** Up - 6
NDA Sales Available Total Generic Sales Available
Yes 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ******* ******* ************ ******* ******* *********** **** **. *** *** ***/*, ****, **** *****,, ****, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** **-**, ****** ** *** ******* ********** ****** ********, *****, ***** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.